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Objective: T cells play an important role in antitumor immunity, and molecules regulating T-cell activity could inﬂuence cancer
susceptibility. The distinct role of coinhibitory receptors in immunosurveillance has been considered. B- and T-lymphocyte attenuator
(BTLA) is one of these receptors, which negatively regulate immune responses. The aim of this study was to investigate the association
between BTLA gene polymorphisms and susceptibility to renal cell carcinoma (RCC) in the Polish population.
Methods: Altogether 282 patients with RCC and 480 healthy subjects were genotyped for the following polymorphisms: rs2705511,
rs1982809, rs9288952, rs16859633, rs9288953, rs2705535, and rs1844089 using the TaqManSNP Genotyping Assays.
Results: Here, we found that the presence of rs1982809G allele (genotype GG þ AG) is associated with increased risk of RCC (odds
ratio ¼ 1.38; 95% CI: 1.03–1.86; P ¼ 0.03). In patients with clear-cell RCC (ccRCC) with high-grade (3 and 4) tumors, the frequency of
rs1982809[GG] genotype was signiﬁcantly higher as compared to those with low-grade (1 and 2) tumors and to the controls (0.14 vs. 0.06,
P ¼ 0.05 and 0.14 vs. 0.06, P ¼ 0.04, respectively). Moreover, we have noticed the trend for overrepresentation of carriers of rs2705511C
allele in patients with RCC as compared with the controls (0.51 vs. 0.44, P ¼ 0.08)
Haplotype rs2705511C/rs1982809G/rs9288952A/rs9288953T/rs2705535C/rs1844089G (CGATCG) increased the risk of RCC of 46%
(odds ratio ¼ 1.46; 95% CI: 1.08–1.96; Pcorrected ¼ 0.05).
Conclusion: Our results indicate that polymorphisms rs1982809 situated in 30 UTR nearby region of BTLA gene might be considered as
low-penetrating risk factor for RCC, but results have to be conﬁrmed in further studies. r 2016 The Authors. Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bon@iitd.pan.wroc.pl, lkarabon@wp.plimmunosurveillance. This process is controlled through soluble
and membrane-bound regulators. Antitumor responses may be
disturbed by regulatory mechanisms, which normally act to
limit T-cell responses following chronic exposure to antigen
[1]. Cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)
and programmed cell death protein 1 (PD-1) are well-known
coinhibitory molecules belonging to the CD28/B7 superfamily,
which act as negative regulators of T-cell activation. B-and
T-lymphocyte attenuator (BTLA) is the third immunoinhibitory
receptor that belongs to this family, but in contrast to PD-1 and
CTLA-4, BTLA binds to the tumor necrosis factor receptoress article under the CC BY-NC-ND license
Table 1
Patient and disease characteristics
N 282
Male 179 (63.5%)
Female 103 (36.5%)
Age
Mean 62.4 (range: 20–85)
Median 62
Histopathology
RCC 282 (100%)
ccRCC 236/282 (83.7%)
Others and unknown 46/282 (16.3%)
Stage at presentation (ccRCC only) 236
I 108 (45.8%)
II 25 (10.6%)
III 26 (11.0%)
IV 77 (32.6%)
Grade (ccRCC only) 236
I 106 (44.9%)
II 73 (30.9%)
III 40 (16.9%)
IV 10 (4.2%)
Unknown 7 (3.0%)
Stage of the disease according to the 2009 TNM system, grading
according to Fuhrman classiﬁcation [10].
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Ligation of BTLA by HVEM induces tyrosine phosphorylation
of immunoreceptor tyrosine-based inhibitory motif and associ-
ation with the src homology domain 2–containing protein
tyrosine phosphatase (SHP)-1or SHP-2 which causes inhibitory
signaling [3]. BTLA is expressed on CD4þ and CD8þ T cells,
B cells, NK T cells, NK cells, DCs, and macrophages [4].
Growing evidence supports the importance of the immune
checkpoints such as CTLA-4, PD-1, and BTLA in RCC
immunotherapy [1,5,6]. To enhance T-cell functions and
consequently antitumor activity, so far monoclonal antibodies
blockading PD-1/PD-L1 and CTLA-4/B7 pathways have
been developed. The new therapeutic agents such as ipili-
mumab, tremelimumab in case of CTLA-4 and nivolumab,
and pembrolizumab and atezolizumab in case of PD-1, have
been tested in clinical trials with promising results [7]. Those
ﬁrst 2 molecules have become standard treatment according
to NCCN Guidelines for Melanoma v.3.2015. It is also
postulated that BTLA/HVEM interaction might be consid-
ered as another target in clinical immunotherapy [6]. Dual
blockade of BTLA and PD-1 revealed encouraging results
intensifying immune antitumor response [8].
Taking into account the importance of coinhibitory molecules
in cancer immunology, we hypothesized that variation in genes
encoding coinhibitory molecules may be associated with suscept-
ibility to renal cell carcinoma (RCC). We have shown previously
that CT60 polymorphism in CTLA-4 gene was associated with
clear-cell RCC (ccRCC) risk, especially with necrosis and
advanced stages of the disease [9]. Consequently, we undertook
a prospective study to investigate the association between BTLA
gene polymorphisms and the risk of RCC in a Polish population.2. Materials and methods
2.1. Subjects
This study was approved by Local Bioethics Committee
(Medical University of Wroclaw—KB—55/2010) and all
individuals involved in this study have signed informed consent.
A total of 282 patients with RCC were prospectively
recruited from the Department of Urology and Oncologic
Urology of Wroclaw Medical University, a tertiary urologic
cancer center. Detailed characteristic of the group of
patients is shown in Table 1. The stage of the disease was
determined according to the 2009 TNM system, and
grading was conducted according to Fuhrman classiﬁcation
[10]. Control subjects were 480 (210 women/270 men)
unrelated healthy volunteers from the same geographic area.
2.2. Selection of single nucleotide polymorphisms
For this study, we have selected the following single
nucleotide polymorphisms (SNPs) described previously in
literature: rs1844089, rs2705535, rs9288953, rs9288952,
and rs16859633 [11–14]. Additionally, we included in thestudy 2 tag dSNPs—rs1982809 and rs2705511 of BTLA
gene, chosen with use of SNPinfo [15] on the basis of the
criteria described [16].
2.3. DNA isolation and genotyping
DNA for each individual was isolated from venous blood
by using the QIAamp DNA Blood Mini Kit (Qiagen,
Germany) according to the manufacturer's protocol. Geno-
typing was performed using the TaqManSNP Genotyping
Assays as described previously [16].
2.4. Statistical analysis
The evaluation of Hardy-Weinberg equilibrium was
performed by comparing the observed and expected frequen-
cies of genotypes using χ2 analysis. The χ2 test was used to
compare categorical data. Odds ratios (OR) and 95% CIs)
were calculated using the binary logistic regression model.
The haplotype frequencies were determined using the SHEsis
program [17]. Haplotypes with frequencieso0.03 were not
considered. Differences were considered statistically signiﬁ-
cant if Po 0.05. For the multiple comparisons, Bonferroni
correction was employed to the level of signiﬁcance.3. Results
Each polymorphism in the BTLA gene was in Hardy-
Weinberg equilibrium in both cases and controls. We found
A. Partyka et al. / Urologic Oncology: Seminars and Original Investigations 34 (2016) 419.e13–419.e19 419.e15that the polymorphism rs16859633, chosen on the basis
of SNPinfo [15] does not occur in the Polish population,
as genotyping of 293 individuals (100 controls/193 patients
with RCC) revealed the presence of only the homo-
zygotes AA.
3.1. BTLA gene polymorphisms and RCC risk
The distributions of the genotypes for all selected poly-
morphisms are presented in Table 2. Our results indicate
that polymorphism rs1982809 is associated with suscepti-
bility to RCC. The rs1982809G allele carriers (dominant
model) were more frequent in patients RCC as comparedTable 2
Distribution of alleles and genotypes of the BTLA SNPs in patients with RCC c
BTLA Cont
N ¼
rs2705511 Genotype A A 265
A C 177
C C 32 (6
Dominant model A A 265
A C þ C C 209
Recessive model A A þ A C 442
C C 32 (6
rs1982809 Genotype A A 279
A G 163
G G 28 (6
Dominant model A A 279
A G þ G G 191
Recessive model A A þ A G 442
G G 28 (6
rs9288952a Genotype A A 425
A G 53 (1
G G 2 (0.
Dominant model A A 425
A G þ G G 55 (1
rs9288953 Genotype C C 186
C T 219
T T 65 (1
Dominant model C C 186
C T þ T T 284
Recessive model C C þ C T 405
T T 65 (1
rs2705535a Genotype C C 464
C T 14 (2
T T 0
Dominant model C C 464
C T þ T T 14 (2
rs1844089a Genotype G G 397
A G 80 (1
A A 2 (0.
Dominant model G G 397
A G þ A A 82 (1
The signiﬁcant results were bolded.
aOwing to low number of mutated homozygotes, the analysis for recessive mo
bFor the control, actual number of individuals for particular SNP genotyping
n ¼ 480; rs9288953, n ¼ 470; rs2705535, n ¼ 478; and rs1844089, n ¼ 47with those of the control (0.49 vs. 0.41, P ¼ 0.03)
(Table 2). Furthermore, we observed trend for the over-
representation of rs2705511C allele carriers (dominant
model) in patients with RCC in comparison with the
controls (0.51 vs. 0.44, P ¼ 0.08).
Taking into account those 2 polymorphisms, we noticed
that individuals possessing predisposing alleles for both
polymorphisms (rs1982809G and rs2705511C carriers)
have 40% increased risk of RCC than individuals possess-
ing [AA] genotype for both SNPs (OR ¼ 1.40; 95% CI:
1.02–1.93; P ¼ 0.04). Haplotype estimation analysis
showed that the haplotype of rs2705511C/rs1982809G/rs-
9288952A/rs9288953T/rs2705535C/rs1844089G (CGATCG)ompared with the controls
rolsb RCC OR [95% CI] P
480 N ¼ 282
(55.9) 139 (49.3) Reference 0.21
(37.3) 122 (43.3) 1.31 [0.97–1.79]
.8) 21 (7.4) 1.25 [0.70–2.25]
(55.9) 139 (49.3) 0.77 [0.57–1.03] 0.08
(44.1) 143 (50.7) 1.30 [0.97–1.75]
(93.2) 261 (92.6) 0.90 [0.51–1.59] 0.72
.8) 21 (7.4) 1.11 [0.63–1.97]
(59.4) 145 (51.4) Reference 0.10
(34.7) 116 (41.1) 1.37 [1.00–1.87]
.0) 21 (7.4) 1.44 [0.79–2.63]
(59.4) 145 (51.4) 0.72 [0.54–0.98] 0.03
(40.6) 137 (48.6) 1.38 [1.03–1.86]
(94.0) 261 (92.6) 0.79 [0.44–1.41] 0.42
.0) 21 (7.4) 1.27 [0.71–2.28]
(88.5) 246 (87.2) Reference 0.78
1.0) 34 (12.1) 1.11 [0.70–1.75]
4) 2 (0.7) 1.73 [0.24–12.34]
(88.5) 246 (87.2) 0.88 [0.56–1.39] 0.59
1.5) 36 (12.8) 1.13 [0.72–1.77]
(39.6) 108 (38.3) Reference 0.42
(46.6) 125 (44.3) 0.98 [0.71–1.36]
3.8) 49 (17.4) 1.30 [0.84–2.02]
(39.6) 108 (38.3) 1.06 [0.78–1.43] 0.73
(60.4) 174 (61.7) 0.95 [0.70–1.28]
(86.2) 233 (82.6) 0.76 [0.51–1.14] 0.19
3.8) 49 (17.4) 1.31 [0.87–1.96]
(97.1) 271 (96.1) Reference 0.38
.9) 10 (3.5) 1.22 [0.54–2.79]
1 (0.4) –
(97.1) 271 (96.1) 0.74 [0.33–1.66] 0.47
.9) 11 (3.9) 1.35 [0.60–3.01]
(82.9) 238 (84.4) Reference 0.43
6.7) 41 (14.5) 0.85 [0.57–1.29]
4) 3 (1.1) 2.50 [0.42–15.08]
(82.9) 238 (84.4) 1.12 [0.75–1.67] 0.59
7.1) 44 (15.6) 0.90 [0.60–1.34]
del was omitted.
was as follow: rs2705511, n ¼ 474; rs1982809, n ¼ 470; rs9288952,
9.
Table 3
Haplotypes frequency of SNPs in BTLA gene in the different group of
patients with RCC and ccRCC compared with the controls
Haplotypea Case (freq) Control (freq) P OR [95% CI]
RCC
N ¼ 282 N ¼ 470b
C G G C C A 9.7 (0.02) 28.6 (0.03) 0.11 0.55 [0.27–1.16]
A A A C C G 249.6 (0.44) 440.5 (0.47) 0.27 0.88 [0.71–1.10]
C A A C C G 23.4 (0.04) 38.8 (0.04) 1.00 1.00 [0.60–1.70]
C G A C C G 20.8 (0.04) 26.1 (0.03) 0.33 1.34 [0.75–2.41]
A A A T C G 110.2 (0.20) 195.7 (0.21) 0.52 0.92 [0.70–1.19]
C G A T C G* 95.9 (0.17) 116.0 (0.12) 0.01 1.46 [1.08–1.96]
ccRCC
N ¼ 236 N ¼ 470b
C G G C C A 9.9 (0.02) 28.6 (0.03) 0.31 0.68 [0.33–1.42]
A A A C C G 214.5 (0.45) 440.5 (0.47) 0.62 0.94 [0.75–1.19]
C A A C C G 19.2 (0.04) 38.8 (0.04) 0.96 0.98 [0.56–1.72]
C G A C C G 17.3 (0.04) 26.1 (0.03) 0.35 1.34 [0.72–2.49]
A A A T C G 86.6 (0.18) 195.7 (0.21) 0.28 0.85 [0.64–1.14]
C G A T C G 76.4 (0.16) 116.0 (0.12) 0.04 1.38 [1.01–1.90]
The signiﬁcant results were bolded.
aThe order of SNPs in estimated analysis of haplotypes frequency:
rs2705511, rs1982809, rs9288952, rs9288953, rs2705535, and rs1844089.
bOnly individuals for whom typing data for all SNPs were included to
the analysis.
*After Bonferoni correction, P ¼ 0.05.
A. Partyka et al. / Urologic Oncology: Seminars and Original Investigations 34 (2016) 419.e13–419.e19419.e16increased risk of RCC of 46% (OR ¼ 1.46; 95% CI: 1.08–
1.96, Pcorrected ¼ 0.05) (Table 3).
3.2. BTLA gene polymorphisms and ccRCC risk
We observed overrepresentation of the rs1982809G
alleles in patients with ccRCC in comparison with the
controls (0.48 vs. 0.41; OR ¼ 1.36; 95% CI: 1.00–1.87;
P ¼ 0.05). For other evaluated SNPs, no differences in
genotype frequencies were found (data not shown). More-
over, there were also no differences in haplotypes' distri-
bution (after Bonferroni correction) between patients with
ccRCC and the controls (Table 3).
3.2.1. BTLA gene polymorphisms in patients with ccRCC in
relation to the grade of tumor: Patients with high-grade
tumors (3 and 4) (ccRCC-HG) vs. patients with low-grade
tumors (1 and 2) and ccRCC-HG vs. the controls
The rs1982809[GG] genotype (recessive model) was
observed more frequently in the ccRCC-HG than in the controls
(0.14 vs. 0.06, P ¼ 0.04) (Table 4). Moreover, the distribution
of genotypes for rs2705535 in patients with ccRCC-HG was
signiﬁcantly different in comparison with the controls (Pcorrected
¼ 0.02), but due to low numbers of tested individuals in
ccRCC-HG group the results must be treated with caution. In
addition, rs9288953[TT] genotype (recessive model) tented to
be more frequent in the ccRCC-HG than in the controls (0.24
vs. 0.14, P ¼ 0.06). Distributions of genotypes for theremaining SNPs and haplotype frequencies did not differ
between patients with ccRCC-HG and the controls.
The frequency of rs9288953[TT] and rs1982809[GG]
genotypes were signiﬁcantly higher in ccRCC-HG as com-
pared with ccRCC-LG (0.24 vs. 0.11, P ¼ 0.02 and 0.14 vs.
0.06, P ¼ 0.05, respectively) (Table 4). We observed also
the differences in genotypes' distribution for rs2705511
between those groups, but these differences did not reach
statistical signiﬁcance (P ¼ 0.06). The distribution of
haplotypes did not differ between patients with ccRCC-HG
and ccRCC-LG and the controls (data not shown).4. Discussion
RCC is an immunogenic tumor characterized by T cells,
NK cells, dendritic cells, and macrophages’ inﬁltration [7,18].
The tumor microenvironment impaired the function of pro-
tective immune cells and antitumor response, but on the
contrary induced suppressive cells like myeloid-derived sup-
pressor cells and cytokines such as MCP-1, IL-1β, and IL-5
[19]. It was shown that in patients with RCC, the levels of
myeloid-derived suppressor cells are signiﬁcantly higher [19].
In the tumor microenvironment, exhaustion of the effector T
cells that mediate antitumor response is demonstrated by cell
surface markers. The important role of coinhibitory molecules
BTLA and PD-1 in this process was shown [8]. Moreover, in
patients with ccRCC, the increased level of exhausted
BTLAþCD8þ T cells was observed [19].
Taking into consideration the important role of coinhi-
bitory molecule in antitumor immunity, we hypothesized
that variations in BTLA gene might inﬂuence cancer
susceptibility in particular susceptibility to RCC.
In the present case-control study, we investigated the
association between 7 selected tagging BTLA SNPs and the
risk of RCC in the Polish population.
Here, we have found that rs1982809 SNP was associated
with RCC risk as well with higher grade of tumor in ccRCC
subgroups of patients. The functional role of this poly-
morphism is not established yet. In 2 databases SNPinfo
and FastSNP [15,20], there are no data about the potential
functional role of these polymorphisms. The rs1982809
SNP is situated in 30 nearby gene region of BTLA between
genes encoding CD200 and BTLA (-101081||-73 bp). Our
results also indicated that rs2705511 that is in moderate
linkage disequilibrium with rs1982809 (r2 = 0.596 [16])
might be associated with RCC risk. This polymorphism is
located in intragenic region between genes encoding CD200
and BTLA (-97820bp||-3334 bp), but closer to CD200 gene.
What is interesting is CD200 is also a type-1 membrane
glycoprotein belonging to the immunoglobulin superfamily.
CD200 has been shown to play an important role in the
regulation of antitumor immunity, and overexpression of
CD200 has been reported in a number of solid tumors
[21–23] and in hematological malignancies [24], as well as
on cancer stem cells [25].
Table 4
Distribution of genotypes of the BTLA SNPs in patients with ccRCC with high-grade tumors (3 and 4) compared with the patients with low-grade tumors (1 and 2) or with the controls
BTLA polymorphism ccRCC high grade
N ¼ 50 (%)
ccRCC low grade
N ¼ 179 (%)
OR [95% CI] P ccRCC high grade
N ¼ 50 (%)
Controls
N ¼ 480 (%)
OR (95% CI) P
rs2705511 Genotype A A 29 (58.0) 86 (48.0) Reference 0.06 29 (58.0) 265 (55.9) Reference 0.30
A C 15 (30.0) 83 (46.4) 0.54 [0.27–1.07] 15 (30.0) 177 (37.3) 0.77 [0.40–1.49]
C C 6 (12.0) 10 (5.6) 1.78 [0.59–5.32] 6 (12.0) 32 (6.8) 1.71 [0.66–4.44]
Dominant model A A 29 (58.0) 86 (48.0) 1.49 [0.79–2.81] 0.21 29 (58.0) 265 (55.9) 1.09 [0.60–1.97] 0.78
A C þ C C 21 (42.0) 93 (52.0) 0.67 [0.36–1.26] 21 (42.0) 209 (44.1) 0.92 [0.51–1.66]
Recesive model A A þ A C 44 (88.0) 169 (94.4) 0.43 [0.15–1.26] 0.12 44 (88.0) 442 (93.2) 0.53 [0.21–1.34] 0.18
C C 6 (12.0) 10 (5.6) 2.30 [0.79–6.69] 6 (12.0) 32 (6.8) 1.88 [0.75–4.75]
rs1982809 Genotype A A 27 (54.0) 91 (50.8) Reference 0.08 27 (54.0) 279 (59.4) Reference 0.10
A G 16 (32.0) 78 (43.6) 0.69 [0.35–1.38] 16 (32.0) 163 (34.7) 1.01 [0.53–1.94]
G G 7 (14.0) 10 (5.6) 2.36 [0.82–6.79] 7 (14.0) 28 (6.0) 2.58 [1.03–6.47]
Dominant model A A 27 (54.0) 91 (50.8) 1.14 [0.61–2.13] 0.69 27 (54.0) 279 (59.4) 0.80 [0.45 –1.44] 0.46
A G þ G G 23 (46.0) 88 (49.2) 0.88 [0.47–1.65] 23 (46.0) 191 (40.6) 1.24 [0.69–2.24]
Recesive Model A A þ A G 43 (86.0) 169 (94.4) 0.36 [0.13–1.01] 0.05 43 (86.0) 442 (94.0) 0.39 [0.16–0.94] 0.04
G G 7 (14.0) 10 (5.6) 2.75 [0.99–7.65] 7 (14.0) 28 (6.0) 2.57 [1.06–6.23]
rs9288952 Genotype A A 43 (86.0) 152 (84.9) Reference 0.57 43 (86.0) 425 (88.5) Reference 0.35
A G 6 (12.0) 26 (14.5) 0.82 [0.32–2.11] 6 (12.0) 53 (11.0) 1.12 [0.45–2.75]
G G 1 (2.0) 1 (0.6) 3.53 [0.22–57.69] 1 (2.0) 2 (0.4) 4.94 [0.44–55.63]
Dominant model A A 43 (86.0) 152 (84.9) 1.09 [0.44–2.68] 0.85 43 (86.0) 425 (88.5) 0.80 [0.34–1.85] 0.60
A G þ G G 7 (14.0) 27 (25.1) 0.92 [0.37–2.25] 7 (14.0) 55 (11.5) 1.26 [0.54–2.93]
rs9288953 Genotype C C 19 (38.0) 71 (39.7) Reference 0.06 19 (38.0) 186 (39.6) Reference 0.14
C T 19 (38.0) 88 (49.2) 0.81 [0.40–1.64] 19 (38.0) 219 (46.6) 0.85 [0.44–1.65]
T T 12 (24.0) 20 (11.2) 2.24 [0.93–5.39] 12 (24.0) 65 (13.8) 1.81 [0.83–3.93]
Dominant model C C 19 (38.0) 71 (39.7) 0.93 [0.49–1.78] 0.83 19 (38.0) 186 (39.6) 1.07 [0.59–1.95] 0.83
C T þ T T 31 (62.0) 108 (60.3) 1.07 [0.56–2.04] 31 (62.0) 284 (60.4) 0.94 [0.51–1.71]
Recesive Model C C þ C T 38 (76.0) 159 (88.8) 0.40 [0.18–0.89] 0.02 38 (76.0) 405 (86.2) 0.51 [0.25–1.02] 0.06
T T 12 (24.0) 20 (11.2) 2.51 [1.13–5.58] 12 (24.0) 65 (13.8) 1.97 [0.98–3.96]
rs2705535 Genotype C C 48 (96.0) 171 (95.5) Reference 0.12 48 (96.0) 464 (97.1) Reference 0.008
C T 1 (2.0) 8 (4.5) 0.45 [0.05–3.65] 1 (2.0) 14 (2.9) 0.69 [0.09–5.37]
T T 1 (2.0) 0 – 1 (2.0) 0 –
Dominant model C C 48 (96.0) 171 (95.5) 1.12 [0.23–5.46] 0.89 48 (96.0) 464 (97.1) 0.72 [0.16–3.28] 0.68
C T þ T T 2 (4.0) 8 (4.5) 0.89 [0.18–4.33] 2 (4.0) 14 (2.9) 1.38 [0.30–6.26]
rs1844089 Genotype A A 42 (84.0) 148 (82.7) Reference 0.83 42 (84.0) 397 (82.9) Reference 0.33
A G 7 (14.0) 29 (16.2) 0.85 [0.35–2.08] 7 (14.0) 80 (16.7) 0.83 [0.36–1.91]
G G 1 (2.0) 2 (1.1) 1.76 [0.16–19.91] 1 (2.0) 2 (0.4) 4.73 [0.42–53.23]
Dominant model A A þ A G 42 (84.0) 148 (82.7) 1.06 [0.45–250] 0.89 42 (84.0) 397 (82.9) 1.08 [0.49–2.40] 0.84
G G 8 (16.0) 31 (17.3) 0.91 [0.39–2.13] 8 (16.0) 82 (17.1) 0.92 [0.42–2.04]
The signiﬁcant results were bolded.
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A. Partyka et al. / Urologic Oncology: Seminars and Original Investigations 34 (2016) 419.e13–419.e19419.e18At present, it is hard to distinguish if the polymorphisms
rs1982809 and rs2705511 inﬂuence or not inﬂuence the
expression of BTLA or CD200 genes or both the genes. We
believe that rs1982809 is associated rather with BTLA
expression, as it is located deﬁnitely closer to BTLA than
CD200 gene. Moreover, our unpublished yet study on
patients with CLL, indicates that this polymorphism is
associated with mRNA expression level of BTLA. Weaker
association of rs2705511 polymorphism with RCC risk
indirectly conﬁrmed this hypothesis.
In the present study, we have also noticed the over-
representation of rs9288953[TT] genotype in patients with
ccRCC with high-grade tumors as compared to the controls
and to patients with ccRCC with low-grade tumors. This SNP
was previously investigated by 2 researchers’ groups in Asian
population. The ﬁrst work was performed by Inuo et al. [13]
who found no associations between this SNP and the risk of
type 1 diabetes mellitus and systemic lupus erythematosus. The
second study performed by Ge at al. [26] showed that
rs9288953 SNP was associated with the risk of colon cancer.
In our previous study, we have found the association between
presence of rs9288953T allele with CLL risk [27]. The
rs9288953 SNP is situated in the ﬁrst intron of BTLA gene.
It is well established that ﬁrst intron is important for splicing
process and may regulate gene expression more efﬁciently than
other introns [28], therefore SNPs situated in this region may
have potential functional role. Ge et al. postulate that according
to human splicing ﬁnder software, rs9288953 SNP could active
6 new splice sites in splicing enhancer motifs and break 1
splicing site in silencer motif and in this way may enhance the
splicing signal and strengthen the expression of BTLA.
To date, only 2 publications present data on an associ-
ation between BTLA gene polymorphisms and cancer. In the
ﬁrst study (mentioned above), Ge et al. [26] investigated the
association between 3 SNPs in BTLA gene: rs1844089,
rs2705535, and rs9288953 and the risk of colon cancer in
Chinese population. The authors found the association
between rs9288953 and rs2705535 SNPs with the colon
cancer risk, whereas for rs1844089 SNP this association
was modiﬁed by pork food intake.
The second study by Fu et al. [12] investigated the
association between rs1844089, rs2705535, rs9288952,
rs2633562, and rs2931761 SNPs and the risk of malignant
breast cancer in Chinese women. The authors observed that
rs1844089, rs2705535, and rs9288952 were associated with
disease risk, tumor size, and estrogen and progesterone
receptor expression, as well as C-erbB and P53 status. Here,
we also noticed associations of rs2705535 polymorphism
with tumor grade, but because of very limited number of
cases in compared group of patients these results must be
treated with caution.
The rs2705535 and rs1844089 SNPs are both situated in
ﬁrst intron of BTLA gene and similarly to rs9288953, these
SNPs might induce the aberrant splicing owing to disruption
of the splice site such as the splicing enhancers, silencers, or
alterations of the mRNA secondary structure [29].The rs9288952 (Cþ800T) was to date the most com-
monly studied SNP, because this polymorphism is a missense
mutation. The nucleotide transition causes amino acid residue
change Pro-Leu in position 219. It was shown that this SNP
is associated with susceptibility to the rheumatoid arthritis in
the Japanese population [14], rheumatoid arthritis in the
Taiwan population [11], and as mentioned above with breast
cancer risk in Chinese women [12]. The functional role of
this polymorphism is not well established. It is postulated that
this amino acid substitution located near the proximal
immunoreceptor tyrosine-based inhibitory motif might dereg-
ulate inhibitory function of BTLA [11].
Our trial has several limitations. Firstly, population
accrued for this trial is based on a tertiary urological cancer
center with overrepresentation of stage III and IV patients,
which might inﬂuence the results of the study. But this fact
gives unique opportunity to study a subpopulation of
patients with aggressive and advanced disease.
Prospective nature of this trial, trying to overcome
selection bias of retrospective studies, causes signiﬁcant
heterogeneity in kidney tumor types. To overcome this
problem, we have selectively analyzed the group of patients
with RCC and additionally separate analysis for the most
common (clear cell) variant of kidney cancer.5. Conclusion
To our knowledge, this study is the ﬁrst prospective,
largest, and most comprehensive evaluation to date of the
association between polymorphisms in the BTLA gene and
RCC. The results of our investigation indicate that poly-
morphisms in BTLA gene, especially rs1982809 SNP might be
considered as potentially low-penetrating risk factor for RCC,
but our results are required to be conﬁrmed in further studies.Conﬂict of interests
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